US 11,865,110 B2
Thrombin inhibitors, formulations, and uses thereof
Kevin Michael Short, Fremont, CA (US); Maria de los Angeles Estiarte-Martinez, Fremont, CA (US); David Ben Kita, Fremont, CA (US); and Nilantha Sudath Sirisoma, Fremont, CA (US)
Assigned to Verseon International Corporation, Dover, DE (US)
Appl. No. 17/259,108
Filed by VERSEON INTERNATIONAL CORPORATION, Dover, DE (US)
PCT Filed Jul. 12, 2019, PCT No. PCT/US2019/041699
§ 371(c)(1), (2) Date Jan. 8, 2021,
PCT Pub. No. WO2020/014669, PCT Pub. Date Jan. 16, 2020.
Claims priority of provisional application 62/697,817, filed on Jul. 13, 2018.
Prior Publication US 2021/0315877 A1, Oct. 14, 2021
Int. Cl. A61K 31/4439 (2006.01); C07D 409/14 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01)
CPC A61K 31/4439 (2013.01) [A61K 9/2095 (2013.01); A61K 9/2846 (2013.01); A61K 9/2893 (2013.01); C07D 409/14 (2013.01)] 20 Claims
 
1. A compound according to Structure I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, solvate, or cocrystal thereof,
wherein R1 is selected from the group consisting of hydrogen and pivaloyl.